Journal of gastroenterology
TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
Hiroki Inada, Sotaro Kurano, Hideaki Miyamoto, Masaya Onishi, Yutaka Suzuki, Satoshi Narahara, Fumiya Otsuka, Etsuko Iio, Takehisa Watanabe, Hiroko Setoyama, Katsuya Nagaoka, Toru Beppu, Hiromitsu Hayashi, Yasuhito Tanaka
Published: 202510.1007/s00535-025-02320-1
Abstract
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with limited treatment options and a poor prognosis. Although immune checkpoint inhibitor (ICI)-based chemotherapy has recently been introduced as a first-line treatment, c…
Preview only. Read the full abstract at the source